CA2666562A1 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies - Google Patents

Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies Download PDF

Info

Publication number
CA2666562A1
CA2666562A1 CA002666562A CA2666562A CA2666562A1 CA 2666562 A1 CA2666562 A1 CA 2666562A1 CA 002666562 A CA002666562 A CA 002666562A CA 2666562 A CA2666562 A CA 2666562A CA 2666562 A1 CA2666562 A1 CA 2666562A1
Authority
CA
Canada
Prior art keywords
treatment
allergies
tal
prevention
thymosin alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666562A
Other languages
English (en)
French (fr)
Inventor
Luigina Romani
Francesco Bistoni
Enrico Garaci
Guido Rasi
Paola Sinibaldi Vallebona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666562A1 publication Critical patent/CA2666562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002666562A 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies Abandoned CA2666562A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2006A000583 2006-10-27
IT000583A ITRM20060583A1 (it) 2006-10-27 2006-10-27 Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
PCT/IT2007/000676 WO2008050362A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies

Publications (1)

Publication Number Publication Date
CA2666562A1 true CA2666562A1 (en) 2008-05-02

Family

ID=39322638

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666562A Abandoned CA2666562A1 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies

Country Status (13)

Country Link
US (1) US20090270594A1 (cg-RX-API-DMAC7.html)
EP (1) EP2083847A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010507649A (cg-RX-API-DMAC7.html)
KR (1) KR20090092267A (cg-RX-API-DMAC7.html)
CN (1) CN101626778A (cg-RX-API-DMAC7.html)
AU (1) AU2007310415A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718019A2 (cg-RX-API-DMAC7.html)
CA (1) CA2666562A1 (cg-RX-API-DMAC7.html)
EA (1) EA200900603A1 (cg-RX-API-DMAC7.html)
IL (1) IL198290A0 (cg-RX-API-DMAC7.html)
IT (1) ITRM20060583A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009004237A (cg-RX-API-DMAC7.html)
WO (1) WO2008050362A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
AR020102A1 (es) * 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
US20060121029A1 (en) * 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
JP4629033B2 (ja) * 2003-03-28 2011-02-09 サイクローン・ファーマシューティカルズ・インコーポレイテッド チモシンα1によるアスペルギルス感染の治療

Also Published As

Publication number Publication date
MX2009004237A (es) 2009-07-07
BRPI0718019A2 (pt) 2013-11-19
WO2008050362A3 (en) 2008-07-10
CN101626778A (zh) 2010-01-13
KR20090092267A (ko) 2009-08-31
AU2007310415A1 (en) 2008-05-02
IL198290A0 (en) 2011-08-01
US20090270594A1 (en) 2009-10-29
JP2010507649A (ja) 2010-03-11
EA200900603A1 (ru) 2009-10-30
WO2008050362A2 (en) 2008-05-02
ITRM20060583A1 (it) 2008-04-28
EP2083847A2 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
Li et al. Baicalin regulates Treg/Th17 cell imbalance by inhibiting autophagy in allergic rhinitis
US20160296596A1 (en) Composition for prevention and treatment of allergic and/or inflammatory diseases
US11344545B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
Siebeneicher et al. Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model
Secor Jr et al. Bromelain limits airway inflammation in an ovalbumin-induced murine model of established asthma
EP2918285A1 (en) Interleukin-2 for treating food allergy
EP2760992A1 (en) Use of hemopexin to sequester hemoglobin
Kim et al. Effects of orally administered Actinidia arguta (Hardy Kiwi) fruit extract on 2-chloro-1, 3, 5-trinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
TW442495B (en) Activated immunoglobulin
US20090270594A1 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
Rodriguez et al. The global helminth belt and Covid-19: the new eosinophilic link
US20050159340A1 (en) Lactoferrin for age related disorders in humans
TW202340233A (zh) 肽用於治療神經退行性疾病或改善認知功能的用途
Bilir et al. Evaluation of the effect of Anatolian propolis on Covid-19 in healthcare professionals: Effect of Anatolian propolis on Covid-19
WO2004041280A1 (en) Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
HK1138513A (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
RU2839802C1 (ru) Способ реабилитации больных с синдромом хронической усталости после перенесенной коронавирусной инфекции на основе пептидных биорегуляторов с помощью спрея сублингвального введения
Hung et al. Regulation of stromal cell-derived factor-1 and exhaled nitric oxide in asthmatic children following montelukast and ketotifen treatment
WO2003037372A1 (en) Method for restoring disordered physiological processes and a medicament for carrying out said method
Melamede Possible mechanisms in autoimmune diseases
CN111214495B (zh) 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用
CN109771446A (zh) 唾液链球菌k12在制备预防和/或治疗自身免疫性疾病的药物中的应用
JP2010507650A (ja) 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ1の使用
Yusuyin et al. Establishment of allergic rhinitis model in mice induced by modified OVA and aluminum adjuvant.
RU2307656C1 (ru) Способ лечения простатита хламидийной этиологии

Legal Events

Date Code Title Description
FZDE Discontinued